KURA News & Events

High-flying semiconductors and memory names were some of the worst-hit stocks on Tuesday as investors - fretting over the speed of the AI and data center demand frenzy - pulled back on Tech exposure.  The worst performer in the S&P 500 - Qualcomm- was down over 11% after the stock's advance of 87% in just 3 weeks at its highs overnight.  Intel, Sandisk, Western Digitaland Micron,were down 7%, 6%, 5%, and 4% respectively, though all four names remain in the top 10 ranking in terms of S&P 500's best performers for the year.  The rotation from high-momentum to value benefited the Healthcare space, which was the best performing sector in the benchmark today but remains the index's worst sector for the year - Humanawas a standout here with a gain of over 7%, as the stock has now nearly doubled from its late-March lows.Sentiment is cautious in the evening session as S&P e-minis and Nasdaq 100 contracts are both flat.  In commodities, WTI Crude Oil remains bid just below $102 per barrel as Middle East tension remains unresolved while base metals continue to trend higher as traders adjust to re-heating inflation expectations, with Copper up for the 4th straight session above $6.60.Check out this evening's top movers from around Wall Street, compiled by The Fly.HIGHER AFTER EARNINGS -Velo3Dup 22.3%SELLAS Life Sciences Groupup 14.4%Nextpowerup 10.5%Arterisup 7.0%ALSO HIGHER -Energy Vaultup 5.1% after announcing strategic development agreement with EskomDOWN AFTER EARNINGS -Karman Holdingsdown 10.4%Resideo Technologiesdown 7.3%Infinity Natural Resourcesdown 7.2%Astronicsdown 5.4%Paysigndown 3.8%Kura Oncologydown 2.1%Oklodown 1.5%

Reports Q1 revenue $18.27M, consensus $25.92M. As of March 31, Kura had $580.8M in cash, cash equivalents and short-term investments, compared to $667.2M as of December 31, 2025. The company believes its cash, cash equivalents and short-term investments as of March 31, when combined with $180M in anticipated payments under the collaboration agreement with Kyowa Kirin, will be sufficient to fund the ziftomenib AML program through the topline results from the first pivotal Phase 3 KOMET-017 frontline trial, anticipated in 2028.

Kura Oncology, (KURA) and Kyowa Kirin (KYKOF) announced that updated results from the frontline arm of the Phase 1 KOMET-007 clinical trial evaluating ziftomenib in combination with cytarabine plus daunorubicin in patients with newly diagnosed NPM1-mutant or KMT2A-rearranged acute myeloid leukemia have been accepted for an oral presentation on Sunday, June 14, 2026, at the upcoming 2026 European Hematology Association Congress in Stockholm, Sweden. The oral presentation will highlight updated results in 99 patients with newly diagnosed NPM1-m or KMT2A-r AML treated with ziftomenib 600 mg once daily in combination with 7+3. These results represent one of the largest datasets reported to date for the evaluation of a menin inhibitor in combination with intensive chemotherapy in frontline AML. As of the abstract data cut-off on January 16, 2026: High response rates across both molecular subtypes; Composite complete response rates of 96% for NPM1-m and 90% for KMT2A-r AML; Deep molecular responses; Measurable residual disease-negativity rates among CRc responders of 83% for NPM1-m and 82% for KMT2A-r AML; Encouraging durability with extended follow-up; Median follow-up of 14.9 months and 9.3 months; Median duration of CRc not reached and 11.2 months; Consistent and manageable safety profile; Safety profile consistent across the NPM1-m and KMT2A-r groups with no new safety signals observed with long-term treatment; Updated analyses with longer median follow-up, central MRD assessment, durability outcomes, and deeper characterization of safety and hematologic recovery will be included at the time of the oral presentation. "With nearly 100 patients treated as well as extended follow-up, ziftomenib in combination with 7+3 continues to demonstrate consistently high response rates, deep MRD negativity, and encouraging durability across genetically defined AML subsets," said Mollie Leoni, CMO. "These data support our belief ziftomenib has potential to serve as a foundational backbone for frontline AML therapy, and we are advancing this regimen in our ongoing Phase 3 registrational program."

Kura Oncology announced new preliminary data from a subset analysis of patients with clear cell renal cell carcinoma previously treated with cabozantinib in the ongoing FIT-001 clinical trial of darlifarnib in combination with cabozantinib. Results were presented at the 2026 International Kidney Cancer Symposium: Europe in Paris, France. The analysis specifically evaluated patients with ccRCC who had previously received cabozantinib, a population that typically derives limited benefit from subsequent therapy. In this setting, the combination of darlifarnib and cabozantinib demonstrated robust antitumor activity along with a manageable safety profile as demonstrated in all RCC patients across multiple dose levels, including full dose cabozantinib. These findings are consistent with clinical and preclinical data presented at the 2025 European Society for Medical Oncology and in earlier data disclosures supporting the potential of darlifarnib to enhance the activity of VEGFR-targeted therapies and to address mechanisms of resistance. Clinical Activity in Cabozantinib-Pretreated Patients: Objective response rate was 44%, with a disease control rate of 94% across all doses tested in this population. Tumor shrinkage observed in 75% of patients, with reductions ranging from 32% to 47% among responders. Antitumor activity observed in a heavily pre-treated, cabozantinib-exposed population, including patients whose best response to prior cabozantinib was stable disease. Responses observed in patients previously treated with cabozantinib in the immediate prior line as well as those who had received other TKIs in addition to cabozantinib. Treatment durations ranged from 8 to 56 weeks, with six patients remaining on therapy at the time of data cutoff. These findings are notable given that patients who progress on cabozantinib are generally considered unlikely to respond to subsequent cabozantinib therapy. "Patients with advanced ccRCC whose disease progresses on cabozantinib have limited treatment options," said Adanma Ayanambakkam, M.D., M.S., Assistant Professor of Hematology Oncology Director of Genitourinary Medical Oncology Research, Stephenson Cancer Center, University of Oklahoma Health Sciences Center. "The tumor shrinkage and high disease control rate observed with darlifarnib in combination with cabozantinib suggest this approach may offer meaningful clinical benefit in a refractory setting or in patients with disease progression after therapy."